for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Aptevo Therapeutics Inc

APVO.OQ

Latest Trade

0.64USD

Change

-0.00(-0.41%)

Volume

13,765

Today's Range

0.63

 - 

0.65

52 Week Range

0.49

 - 

4.35

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
0.64
Open
0.65
Volume
13,765
3M AVG Volume
11.12
Today's High
0.65
Today's Low
0.63
52 Week High
4.35
52 Week Low
0.49
Shares Out (MIL)
45.10
Market Cap (MIL)
28.95
Forward P/E
-0.56
Dividend (Yield %)
--

Latest Developments

More

Aptevo Therapeutics Q2 Loss Per Share $0.30

Aptevo Therapeutics Reports Continued Progress In Apvo210 And Apvo436 Clinical Trials

Aptevo Therapeutics Reports Q1 Loss Per Share $0.44

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Aptevo Therapeutics Inc

Aptevo Therapeutics Inc. is a biotechnology company. The Company is focused on oncology and hematology therapeutics. The Company is engaged in the discovery, development, commercialization and sale of oncology and hematology therapeutics. The Company's technology is the ADAPTIR (modular protein technology) platform. The Company has approximately four products in the areas of hematology and infectious diseases, as well as various investigational-stage product candidates in immuno-oncology. The Company's investigational-stage product candidates include MOR209/ES414, ES210, ES425, Otlertuzumab and 5E3. Its technology can produce monospecific and multispecific immunotherapeutic proteins that bind to various targets. The Company's marketed products are WinRho SDF (Rho(D) Immune Globulin Intravenous (Human)), HepaGam B (Hepatitis B Immune Globulin Intravenous (Human)), VARIZIG (Varicella Zoster Immune Globulin (Human)), and IXINITY (coagulation factor IX (recombinant)).

Industry

Biotechnology & Drugs

Contact Info

2401 4th Ave Ste 1050

+1.206.8380500

http://aptevotherapeutics.com/

Key Stats

1.67 mean rating - 3 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-2.050

2017

0.330

2018

-2.390

2019(E)

-1.155
Price To Earnings (TTM)
--
Price To Sales (TTM)
1.09
Price To Book (MRQ)
1.10
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
74.65
LT Debt To Equity (MRQ)
74.65
Return on Investment (TTM)
-85.61
Return on Equity (TTM)
-66.58

Latest News

Latest News

BRIEF-Aptevo Therapeutics Begins Patient Dosing In Phase 2 Clinical Trial Of Otlertuzumab In Peripheral T-Cell Lymphoma

* APTEVO THERAPEUTICS BEGINS PATIENT DOSING IN PHASE 2 CLINICAL TRIAL OF OTLERTUZUMAB IN PERIPHERAL T-CELL LYMPHOMA Source text for Eikon: Further company coverage:

BRIEF-Aptevo Therapeutics Announces Plans To Conduct Phase 2 Study Of Otlertuzumab In Peripheral T-Cell Lymphoma

* APTEVO THERAPEUTICS ANNOUNCES PLANS TO CONDUCT PHASE 2 STUDY OF OTLERTUZUMAB IN PERIPHERAL T-CELL LYMPHOMA

BRIEF-Aptevo Therapeutics files mixed shelf of up to $150 mln

* Aptevo Therapeutics Inc files for mixed shelf of up to $150 million - SEC filing Source text for Eikon: (http://bit.ly/2hvzJMI) Further company coverage:

BRIEF-Aptevo Therapeutics reports third quarter 2017 financial results

* Aptevo Therapeutics reports third quarter 2017 financial results

BRIEF-Aptevo Therapeutics and Alligator Bioscience announced further details of collaboration on ALG.APV-527​

* Aptevo Therapeutics Inc - co, Alligator Bioscience announced further details of companies' collaboration on ALG.APV-527 Source text for Eikon: Further company coverage:

BRIEF-APTEVO THERAPEUTICS ‍AMENDS TERMS OF CREDIT AGREEMENT

* APTEVO THERAPEUTICS INC - AMENDED TERMS OF A CREDIT AGREEMENT INITIALLY EXECUTED WITH MIDCAP FINANCIAL TRUST IN AUGUST 2016

BRIEF-Aptevo Therapeutics and MorphoSys ends joint agreement to develop and commercialize MOR209/ES414

* Aptevo Therapeutics and MorphoSys end joint development and commercialization agreement for MOR209/ES414

BRIEF-Aptevo Therapeutics signs agreement for up to $74.5 mln to sell Hyperimmune Commercial Products

* Aptevo Therapeutics signs agreement for up to $74.5 million to sell hyperimmune commercial products

BRIEF-Aptevo and Alligator Bioscience start IND-enabling development activities immunotherapy drug

* Aptevo Therapeutics and Alligator Bioscience commence IND-enabling development activities for new bispecific immunotherapy candidate ALG.APV-527 Source text for Eikon: Further company coverage:

BRIEF-Aptevo Therapeutics and Alligator Bioscience announce plans to co-develop novel bispecific antibody for tumor-directed immunotherapy

* Aptevo Therapeutics and Alligator Bioscience announce plans to co-develop novel bispecific antibody for tumor-directed immunotherapy

BRIEF-Aptevo Therapeutics' unit, CMC ICOS Biologics enter non-exclusive amended and restated commercial supply agreement

* Aptevo Therapeutics- on June 17, unit and CMC ICOS biologics entered non-exclusive amended and restated commercial supply agreement - SEC filing

BRIEF-Aptevo Therapeutics presents clinical data on safety and efficacy of Ixinity in children with Hemophilia B

* Aptevo Therapeutics presents new clinical data evaluating the safety and efficacy of Ixinity in children with Hemophilia B

BRIEF-Aptevo Therapeutics reports new ixinity supply

* Aptevo Therapeutics announces new ixinity supply available May 2017 Source text for Eikon: Further company coverage:

BRIEF-Aptevo Therapeutics receives $20 mln payment from Emergent Biosolutions

* Aptevo Therapeutics receives $20 million payment from Emergent Biosolutions

BRIEF-Aptevo Therapeutics anticipated experiencing supply interruption of Ixinity 1,500 IU dosage form beginning Dec 2016 - SEC filing

* Aptevo Therapeutics says on Nov 14, reported co anticipated experiencing supply interruption of Ixinity 1,500 IU dosage form beginning Dec 2016 - SEC filing

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up